Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine if evidence-based guidance on follow-up care and self-management provided to PCPs and patients, respectively, reduces relapses within 90 days for acute asthma (primary outcome). Secondary outcomes will include follow-up visits with the primary care provider, patients' quality of life and cost-effectiveness indicators.


Clinical Trial Description

This prospective, randomized, open label study will include asthmatics 17-55 years of age with no evidence of chronic obstructive pulmonary disease. Patients will be eligible if they visit one of four Emergency Departments (EDs) in Edmonton or Calgary and receive treatment for acute asthma resulting in discharge home. All patients should have a primary care provider (PCP: Family Physician, Internist or Nurse Practitioner) with whom to follow-up or one will be found for them. At discharge patients will be randomized into three groups: A: Usual care; PCPs will receive a faxed copy of the ED chart and patients will receive a discharge plan and a paper-based educational pamphlet (treatment in the ED and at discharge will be left to ED physicians' discretion); B: Usual care + personalized fax to the patients' PCP including a copy of the ED chart and a opinion-leader (OL) letter encouraging follow-up within two weeks and providing management suggestions; or C: Usual care + personalized fax to the patients' PCP including the OL letter as described above + involvement of a case manager who will encourage patients' to pursue follow-up, provide management review and offer brief education within the next week. Outcomes will be ascertained blinded to treatment allocation through telephone follow-up at 30 and 90 days. A sample of 366 patients (122 per group) is required based on the proportion with relapse at 90 days (40%) and a chi-square test of association and post-hoc tests (groups A vs. B, groups B vs. C). This sample will allow for the detection of an moderate effect size of at least 0.171, and a difference between groups A and B of 50% (i.e., 40% vs. 20%) and between groups B and C of 75% (i.e., 20% vs. 5%) using two-sided z-tests, 80% power, α=0.025. Intention to treat analyses will be conducted. Relapse rates by group and associated 95% confidence intervals (CI) will be calculated. Proportions among groups will be compared using chi-square tests and if statistically significant, separate proportion tests will compare pairs of groups adjusting for multiple testing. A multivariable logistic regression model will adjust effect estimates for potential baseline imbalances and site-specific differences in effectiveness. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01079000
Study type Interventional
Source University of Alberta
Contact
Status Completed
Phase N/A
Start date June 2012
Completion date March 2016

See also
  Status Clinical Trial Phase
Completed NCT01429415 - Magnesium Nebulization Utilization in Management of Pediatric Asthma Phase 2
Completed NCT01196377 - Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study N/A
Completed NCT00733317 - Budesonide for Emergency Treatment of Acute Wheezing in Children Phase 4
Completed NCT00733473 - Nebulized Budesonide for Children Who Are Hospitalized for Acute Wheezing Phase 4
Completed NCT01695031 - Feasibility of an ED Initiated Online Asthma Management Program for Urban Teens N/A
Recruiting NCT04016220 - Nebulized Budesonide Combined With Systemic Corticosteroid in Acute Severe Asthma Phase 1
Active, not recruiting NCT06005337 - Supporting Parents to Choose Wisely N/A
Completed NCT00922350 - Heliox and Posture in Patients With Asthma N/A
Completed NCT03698630 - Single Dose Oral Dexamethasone Versus Multi-dose Prednisolone in the Treatment of Acute Exacerbations of Asthma in Children Phase 4
Terminated NCT00819637 - A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients Phase 4
Completed NCT01868113 - Inhaled Corticosteroids in U-5 Children With Acute Respiratory Infection in Uganda: A Randomised Trial Phase 3
Completed NCT01016444 - Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms
Completed NCT00393367 - Budesonide Inhalation Suspension for Acute Asthma in Children Phase 4
Completed NCT03369119 - Effect of Addition Oral Montelukast to Standard Treatment in Acute Asthma in Hospitalized Preschool Children Phase 4
Completed NCT01304901 - Effect of Addition of Single Dose of Oral Montelukast to Standard Treatment in Acute Asthma in Preschool Children. Phase 4
Completed NCT01403467 - Impact of Continuous Positive Airway Pressure on the Treatment of Acute Asthma Exacerbation Phase 4